For the quarter ending 2025-09-30, STOK had -$18,152K decrease in cash & cash equivalents over the period. -$30,498K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -38,348 | 89,397 |
| Depreciation | 442 | 923 |
| Amortization and accretion of marketable securities | -615 | 33 |
| Stock-based compensation | 8,039 | 14,351 |
| Impairment of right of use asset | 696 | - |
| Loss on disposal of property and equipment | 8 | - |
| Reduction in the carrying amount of right of use assets | 547 | 1,211 |
| Accounts receivable | 7,580 | - |
| Prepaid expenses and other current assets | -5,640 | 6,405 |
| Accounts payable, accrued liabilities and lease liabilities | 4,881 | 7,506 |
| Deferred revenue | -4,060 | -611 |
| Net cash provided by (used in) operating activities | -30,366 | 106,405 |
| Purchases of marketable securities | 23,925 | 200,569 |
| Purchases of property and equipment | 132 | 306 |
| Sales of marketable securities | 33,151 | 66,030 |
| Net cash used in investing activities | 9,094 | -134,845 |
| Proceeds from employee stock purchase plan | 632 | 370 |
| Proceeds from issuance of common stock upon exercise of stock options | 2,488 | 1,558 |
| Net cash provided by financing activities | 3,120 | 1,928 |
| Net decrease in cash, cash equivalents and restricted cash | -18,152 | -26,512 |
| Cash and cash equivalents at beginning of period | 128,779 | - |
| Cash and cash equivalents at end of period | 84,115 | - |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)